Browse studies

Find your next paid study

1 recruiting study matching your filters

A Phase II Study of Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

This is the first study to be done in a newly described class of neuroendocrine tumors known as well-differentiated grade 3 neuroendocrine tumors (WD G3 NET). …

Neuroendocrine TumorsWell-Differentiated Neuroendocrine CarcinomaHigh Grade Neuroendocrine Carcinoma, Any Site

University of California, San FranciscoNCT05746208